The creator of "using oil for skincare", Lin Qingxuan, has obtained approval from the China Securities Regulatory Commission and updated the prospectus, accelerating the process of going public.
After receiving the notice of record-filing from the China Securities Regulatory Commission recently, Lin Qingxuan has accelerated the listing process. On December 2, the Hong Kong Stock Exchange website showed that Shanghai Lin Qingxuan Cosmetics Group Co., Ltd. has updated its IPO application materials.
Following the recent receipt of the CSRC filing notice, Lin Qingxuan has accelerated the listing process. On December 2nd, the Hong Kong Stock Exchange website showed that Shanghai Lin Qingxuan Cosmetics Group Co., Ltd. has updated its IPO application materials.
As a pioneer in the "oil-based skincare" track, Lin Qingxuan has been focusing on anti-wrinkle and firming skincare products for many years. It has developed into a leading brand of cell-level anti-wrinkle essential oils and successfully expanded its products to mainstream skincare categories such as creams, toners, lotions, essences, masks, and sunscreens. According to data from Zhaoshizixun, based on all-channel retail sales, the company's core product - Lin Qingxuan Camellia Anti-Wrinkle Repair Essence Oil has been the top-selling facial essence oil product in the country for the past 11 years since 2014.
Thanks to the stable sales of its innovative flagship products and the continuous introduction of various product categories, the company's total revenue has maintained growth over the past three years, with a growth rate far exceeding the industry average. The prospectus shows that the company's total revenue has increased from 691 million yuan in 2022 to 1.21 billion yuan in 2024, with a compound annual growth rate of 32.3%. In the first half of this year, the company's profitability further enhanced, achieving a net profit of 182 million yuan, with a gross profit margin as high as 82.4%, with the essence oil category having a gross profit margin of 86.2%.
In terms of specific product sales performance, Lin Qingxuan Camellia Black Gold Time Peptide Anti-Wrinkle Brightening Essence Cream generated revenue of 61.5 million yuan in 2024 and has already reached 50 million yuan in the first half of 2025, becoming one of Lin Qingxuan's best-selling products. The Lin Qingxuan High SPF Isolation Sunscreen rapidly developed since its launch in 2024, generating 36.3 million yuan in its first year on the market and increasing to 42.1 million yuan in revenue in the first half of this year, further proving the high market recognition of the company's product strength.
With the continuous development of the Chinese economy and the popularity of social media, the concept of delicate skincare is deepening, driving anti-wrinkle, firming, and repairing skincare products to become important growth points in the industry. The rise of domestic brands can further stimulate consumers' cultural resonance and confidence.
According to Zhaoshizixun, the market size of high-end anti-wrinkle and firming skincare products is expected to increase from 59.4 billion yuan in 2024 to 155.5 billion yuan in 2029, with a compound annual growth rate of 21.2%. By 2029, the Chinese high-end skincare industry is expected to reach 218.5 billion yuan, with a compound annual growth rate of 13.8% from 2024 to 2029. Market analysts believe that as a leading brand in the high-end domestic skincare industry, Lin Qingxuan will benefit first from its strong research and development innovation capabilities and existing leading products.
Related Articles

Jiangsu Hengrui Pharmaceuticals (01276) has adjusted 20 products/indications to the new national medical insurance list. Among them, 10 products are included for the first time.

CHINA BOTON (03318) will be suspended from trading starting December 8th for a short period, awaiting the announcement of a significant sale transaction.

GMTEight List of A-share restricted sales and lifting restrictions | December 8th
Jiangsu Hengrui Pharmaceuticals (01276) has adjusted 20 products/indications to the new national medical insurance list. Among them, 10 products are included for the first time.

CHINA BOTON (03318) will be suspended from trading starting December 8th for a short period, awaiting the announcement of a significant sale transaction.

GMTEight List of A-share restricted sales and lifting restrictions | December 8th






